JP2017511152A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511152A5
JP2017511152A5 JP2017501125A JP2017501125A JP2017511152A5 JP 2017511152 A5 JP2017511152 A5 JP 2017511152A5 JP 2017501125 A JP2017501125 A JP 2017501125A JP 2017501125 A JP2017501125 A JP 2017501125A JP 2017511152 A5 JP2017511152 A5 JP 2017511152A5
Authority
JP
Japan
Prior art keywords
antigen
binding polypeptide
domain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511152A (ja
JP6640181B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021668 external-priority patent/WO2015143271A1/en
Publication of JP2017511152A publication Critical patent/JP2017511152A/ja
Publication of JP2017511152A5 publication Critical patent/JP2017511152A5/ja
Application granted granted Critical
Publication of JP6640181B2 publication Critical patent/JP6640181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501125A 2014-03-21 2015-03-20 二重特異性抗原結合ポリペプチド Active JP6640181B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968437P 2014-03-21 2014-03-21
US61/968,437 2014-03-21
PCT/US2015/021668 WO2015143271A1 (en) 2014-03-21 2015-03-20 Bi-specific antigen-binding polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233759A Division JP7048567B2 (ja) 2014-03-21 2019-12-25 二重特異性抗原結合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2017511152A JP2017511152A (ja) 2017-04-20
JP2017511152A5 true JP2017511152A5 (enExample) 2018-04-19
JP6640181B2 JP6640181B2 (ja) 2020-02-05

Family

ID=54145363

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017501125A Active JP6640181B2 (ja) 2014-03-21 2015-03-20 二重特異性抗原結合ポリペプチド
JP2019233759A Expired - Fee Related JP7048567B2 (ja) 2014-03-21 2019-12-25 二重特異性抗原結合ポリペプチド
JP2022007025A Pending JP2022062083A (ja) 2014-03-21 2022-01-20 二重特異性抗原結合ポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019233759A Expired - Fee Related JP7048567B2 (ja) 2014-03-21 2019-12-25 二重特異性抗原結合ポリペプチド
JP2022007025A Pending JP2022062083A (ja) 2014-03-21 2022-01-20 二重特異性抗原結合ポリペプチド

Country Status (10)

Country Link
US (2) US10202462B2 (enExample)
EP (2) EP3712176A1 (enExample)
JP (3) JP6640181B2 (enExample)
KR (1) KR102399028B1 (enExample)
CN (2) CN106164094B (enExample)
AU (2) AU2015231155B2 (enExample)
CA (1) CA2943242A1 (enExample)
ES (1) ES2800674T3 (enExample)
RU (1) RU2723940C2 (enExample)
WO (1) WO2015143271A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2800674T3 (es) * 2014-03-21 2021-01-04 X Body Inc Polipéptidos biespecíficos de unión a antígeno
CN106279435B (zh) * 2016-08-16 2019-06-07 新乡医学院 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用
WO2020055756A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020071881A1 (ko) 2018-10-05 2020-04-09 서울대학교산학협력단 Pdgf 수용체에 대한 항체 및 이의 용도
MX2022012076A (es) * 2020-05-21 2022-10-13 Zydus Lifesciences Ltd Variante del fc y preparacion de la misma.
AU2022300881A1 (en) * 2021-06-29 2024-01-18 Elpis Biopharmaceuticals Anti-nectin4 antibodies and multi-specific protein complexes comprising such
KR20230060546A (ko) * 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
AU3369999A (en) 1998-04-02 1999-10-25 Genentech Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
CN101987871A (zh) 2002-09-27 2011-03-23 赞科股份有限公司 优化的Fc变体及其产生方法
WO2004035752A2 (en) 2002-10-15 2004-04-29 Protein Design Labs, Inc. ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
JP2008512352A (ja) * 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
KR20150140417A (ko) * 2004-07-22 2015-12-15 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
KR101443473B1 (ko) * 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US20060263367A1 (en) * 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
EP1986684A2 (en) * 2006-02-15 2008-11-05 ImClone Systems Incorporated Functional antibodies
EP2799449A1 (en) 2006-05-25 2014-11-05 Bayer Intellectual Property GmbH Dimeric molecular complexes
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US20090304590A1 (en) 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2009068627A2 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
AU2010230563A1 (en) 2009-04-02 2011-09-22 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain Fab fragments
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
WO2011130580A1 (en) 2010-04-15 2011-10-20 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
JP6040148B2 (ja) * 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
WO2012065055A2 (en) * 2010-11-12 2012-05-18 The Rockefeller University Fusion proteins for hiv therapy
EP2686349B1 (en) * 2011-03-15 2020-12-09 X-Body, Inc. Antibody screening methods
US20140170149A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CN107353342B (zh) * 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
ES2800674T3 (es) * 2014-03-21 2021-01-04 X Body Inc Polipéptidos biespecíficos de unión a antígeno

Similar Documents

Publication Publication Date Title
JP2020500538A5 (enExample)
JP2017511152A5 (enExample)
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
JP2017505125A5 (enExample)
JP2015535828A5 (enExample)
JP2017535257A5 (enExample)
IL257281A (en) Anti-pd-1 antibodies and methods of using them
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
RU2016100892A (ru) Антитела против tweakr и их применение
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
HRP20211444T1 (hr) Anti-dll3 antitijelo
HRP20200745T1 (hr) Agensi koji vezuju cd123 i njihove upotrebe
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
FI3922645T3 (fi) Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
RU2020129387A (ru) Антитела к pd-1 собак
HRP20201503T1 (hr) MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
JP2014205674A5 (enExample)